Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide standard versus optimized monthly dosing for anemia in chronic kidney disease
ChiCTR2400093814Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2024
- Modality
- PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peglmolesatide in Uraemic Anaemia (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Change in mean hemoglobin from baseline at week 24. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
peglmolesatide
03
Conditions
Uraemic Anaemia
Beyond the preview
Go deeper on ChiCTR2400093814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093814.